<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">morpho</journal-id><journal-title-group><journal-title xml:lang="ru">Морфологические ведомости</journal-title><trans-title-group xml:lang="en"><trans-title>Morphological newsletter</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1812-3171</issn><issn pub-type="epub">2686-8741</issn><publisher><publisher-name>Private Medical University REAVIZ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20340/mv-mn.18(26).02.45-48</article-id><article-id custom-type="elpub" pub-id-type="custom">morpho-120</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT ARTICLES</subject></subj-group></article-categories><title-group><article-title>СРАВНИТЕЛЬНЫЙ МОРФОЛОГИЧЕСКИЙ АНАЛИЗ НЕФРОТОКСИЧНОСТИ ДОКСОРУБИЦИНА И НАНОСТРУКТУРИРОВАННОГО ДОКСОРУБИЦИНА В УСЛОВИЯХ ПЕРЕВИВАЕМОГО КАНЦЕРОГЕНЕЗА</article-title><trans-title-group xml:lang="en"><trans-title>THE COMPARATIVE MORPHOLOGICAL ANALYSIS OF THE NEPHROTOXICITY OF DOXORUBICIN AND NANOSTRUCTURED DOXORUBICIN IN CONDITIONS OF TRANSPLANTABLE CARCINOGENESIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чаиркин</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Chairkin</surname><given-names>I. N.</given-names></name></name-alternatives><email xlink:type="simple">chairkin@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чаиркина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chairkina</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">chairkinanata@rambler.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дерябина</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Deryabina</surname><given-names>O. N.</given-names></name></name-alternatives><email xlink:type="simple">dr.deryabina@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Медвежонков</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Medvezhonkov</surname><given-names>V. Y.</given-names></name></name-alternatives><email xlink:type="simple">medvejonkov.v@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калмин</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalmin</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">ovkalmin@gmail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный исследовательский Мордовский государственный университет им. Н.П. Огарева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ogarev National Research Mordovian State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Пензенский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Penza State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2018</year></pub-date><volume>26</volume><issue>2</issue><fpage>45</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чаиркин И.Н., Чаиркина Н.В., Дерябина О.Н., Медвежонков В.Ю., Калмин О.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Чаиркин И.Н., Чаиркина Н.В., Дерябина О.Н., Медвежонков В.Ю., Калмин О.В.</copyright-holder><copyright-holder xml:lang="en">Chairkin I.N., Chairkina N.V., Deryabina O.N., Medvezhonkov V.Y., Kalmin O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.morpholetter.com/jour/article/view/120">https://www.morpholetter.com/jour/article/view/120</self-uri><abstract><p>Исследование проведено на 120 беспородных белых лабораторных крысах, которым производили перевивку животным асцитной гепатомы Зайдела, которых разделили на три равные по численности группы. Из них первая группа животных была контрольной группой без лечения. Во второй группе животным вводился доксорубицин, в третьей группе животным вводился наноструктурированный доксорубицин в течение 21 суток. Целью исследования явилась оценка степени морфологических изменений в канальцах и клубочках почек под влиянием наноструктурированного доксорубицина и доксорубицина в условии перевиваемого канцерогенеза. Учитывая нефротоксичность изучаемых химиопрепаратов, изучали динамику структурных изменений в канальцах и клубочках почек. Проводили сравнительную морфологическую оценку возникающих в почках изменений. Полученные в ходе работы результаты морфологического исследования структурных компонентов почек доказывают, что доксорубицин и наноструктурированный доксорубицин оказывают различное воздействие, как на канальцевый аппарат, так и на клубочки почек в условии перевиваемого канцерогенеза. Применение доксорубицина сопровождается сравнительно выраженным нефротоксичным эффектом, показателем чего являются дистрофические и некробиотические изменения эпителия извитых канальцев и клубочкового аппарата почек. Использование наноструктурированного доксорубицина ограничивается умеренно выраженными дистрофическими изменениями эпителия канальцевого аппарата почек, клубочковый аппарат при этом остается интактным. Таким образом, использование для лечения асцитной гепатомы Зайдела у экспериментальных животных препарата наноструктурированного доксорубицина оказывает менее выраженное токсическое и повреждающее действие на паренхиму почек.</p></abstract><trans-abstract xml:lang="en"><p>The study was carried out on 120 mongrel white laboratory rats, to whom were transplanted the ascitiс Zaidel's hepatoma and which were divided into three equal groups. Of these, the first group of animals was a control group without treatment. In the second group, to animals doxorubicin was injected, in the third group, nanostructured doxorubicin was injected to the animals for 21 days. The aim of the study was to assess the degree of morphological changes in the tubules and glomeruli of the kidneys under the influence of nanostructured doxorubicin and doxorubicin in the condition of transplantable carcinogenesis. Given the nephrotoxicity of the chemotherapy drugs studied, the dynamics of structural changes in the tubules and glomeruli of the kidneys was studied. Conducted a comparative morphological evaluation of the changes occurring in the kidneys. The results of a morphological study of the structural components of the kidneys prove that doxorubicin and nanostructured doxorubicin have different effects on both the tubular apparatus and the glomeruli of the kidneys in the condition of transient carcinogenesis. The use of doxorubicin is accompanied by a relatively pronounced nephrotoxic effect, which is indicated by dystrophic and necrobiotic changes in the epithelium of convoluted tubules and the glomerular apparatus of the kidneys. The use of nanostructured doxorubicin is limited to moderately expressed dystrophic changes in the epithelium of the tubular apparatus of the kidneys, the glomerular apparatus remains intact at the same time. Thus, the use of the preparation of nanostructured doxorubicin for the treatment of the ascitic hepatoma of Zaidel in experimental animals has a less pronounced toxic and damaging effect on the renal parenchyma.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нанофармакология опухолей</kwd><kwd>наноструктурированный доксорубицин</kwd><kwd>перевиваемый канцерогенез</kwd><kwd>асцитная гепатома Зайдела</kwd><kwd>нефротоксичность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>nanopharmacology of tumors</kwd><kwd>nanostructured doxorubicin</kwd><kwd>transplantable carcinogenesis</kwd><kwd>Zaidel's ascitic hepatoma</kwd><kwd>nephrotoxicity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Reshetarova DA. Analiz onkologicheskoj zabolevaemosti naseleniya PFO [Elektronnyj resurs] Sovremennye problemy territorial'nogo razvitiya: elektron. zhurn. 2018;2 ID 39 ISSN:2542-2103.</mixed-citation><mixed-citation xml:lang="en">Reshetarova DA. Analiz onkologicheskoj zabolevaemosti naseleniya PFO [Elektronnyj resurs] Sovremennye problemy territorial'nogo razvitiya: elektron. zhurn. 2018;2 ID 39 ISSN:2542-2103.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Terasaki T, Iga T, Sugiyama Y, Sawada Y, Hanano M. Nuclear binding as a determinant of tissue distribution of adriamycin, daunomycin, adriamycinol, daunorubicinol and actinomycin D. J Pharmacobiodyn. 1984;7(5):269-277.</mixed-citation><mixed-citation xml:lang="en">Terasaki T, Iga T, Sugiyama Y, Sawada Y, Hanano M. Nuclear binding as a determinant of tissue distribution of adriamycin, daunomycin, adriamycinol, daunorubicinol and actinomycin D. J Pharmacobiodyn. 1984;7(5):269-277.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Matyash MG, Kravchuk TL, Vysockaya VV, Chernov VI, Gol'dberg VE. Inducirovannaya antraciklinami kardiotoksichnost': mekhanizm razvitiya i klinicheskie proyavleniya. Sibirskij onkologicheskij zhurnal. 2008;6(30):66-75.</mixed-citation><mixed-citation xml:lang="en">Matyash MG, Kravchuk TL, Vysockaya VV, Chernov VI, Gol'dberg VE. Inducirovannaya antraciklinami kardiotoksichnost': mekhanizm razvitiya i klinicheskie proyavleniya. Sibirskij onkologicheskij zhurnal. 2008;6(30):66-75.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ipatova OM, Zykova MG, Torhovskaya TI, Medvedeva NV, Prozorovskij VN. Vozmozhnosti ispol'zovaniya fosfolipidnoj nanosistemy s glicirrizinovoj kislotoj (Fosfogliv) dlya optimizacii lekarstvennyh preparatov, na primere doksorubicina i budesonida. Biomedicinskaya himiya. 2009;55(2):185-194.</mixed-citation><mixed-citation xml:lang="en">Ipatova OM, Zykova MG, Torhovskaya TI, Medvedeva NV, Prozorovskij VN. Vozmozhnosti ispol'zovaniya fosfolipidnoj nanosistemy s glicirrizinovoj kislotoj (Fosfogliv) dlya optimizacii lekarstvennyh preparatov, na primere doksorubicina i budesonida. Biomedicinskaya himiya. 2009;55(2):185-194.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pyataev NA, Shchukin SA, Korovina EYu, Zyrnyaeva NN. Osobennosti tkanevogo raspredeleniya i protivoopuholevoj aktivnosti doksorubicina pri vvedenii v forme kon"yugata s DNK u krys s transplantirovannoj karcinomoj RS-1. Rossijskij bioterapevticheskij zhurnal. 2011;10(2):55-61.</mixed-citation><mixed-citation xml:lang="en">Pyataev NA, Shchukin SA, Korovina EYu, Zyrnyaeva NN. Osobennosti tkanevogo raspredeleniya i protivoopuholevoj aktivnosti doksorubicina pri vvedenii v forme kon"yugata s DNK u krys s transplantirovannoj karcinomoj RS-1. Rossijskij bioterapevticheskij zhurnal. 2011;10(2):55-61.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ying XY, Du YZ, Chen WW, Yuan H, Hu FQ. Preparation and characterization of modified lipid nanoparticles for doxorubicin controlled release. Pharmazie. 2008;63(12):878-882.</mixed-citation><mixed-citation xml:lang="en">Ying XY, Du YZ, Chen WW, Yuan H, Hu FQ. Preparation and characterization of modified lipid nanoparticles for doxorubicin controlled release. Pharmazie. 2008;63(12):878-882.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Allen TM, Cullis PR. Liposomal drag delivery system: From concept to clinical applications. Adv Drag Deliv Rev. 2013;65:36-48.</mixed-citation><mixed-citation xml:lang="en">Allen TM, Cullis PR. Liposomal drag delivery system: From concept to clinical applications. Adv Drag Deliv Rev. 2013;65:36-48.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Alekseev KV, Alyautdin RN, Blynskaya EV, Kvinh BT. Nanorazmernye sistemy dostavki lekarstvennyh veshchestv. Vestnik novyh medicinskih tekhnologij. 2009;16(2):17-20.</mixed-citation><mixed-citation xml:lang="en">Alekseev KV, Alyautdin RN, Blynskaya EV, Kvinh BT. Nanorazmernye sistemy dostavki lekarstvennyh veshchestv. Vestnik novyh medicinskih tekhnologij. 2009;16(2):17-20.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Baryshnikov AYu. Nanostrukturirovannye liposomal'nye sistemy kak sredstvo dostavki protivoopuholevyh preparatov. Vestnik RAMN. 2012;3:23-30.</mixed-citation><mixed-citation xml:lang="en">Baryshnikov AYu. Nanostrukturirovannye liposomal'nye sistemy kak sredstvo dostavki protivoopuholevyh preparatov. Vestnik RAMN. 2012;3:23-30.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tsyganova NA, Khayrullin RM, Terentyuk GS, et al. Pronitsaemost' pegilirovannykh zolotykh nanochastits cherez gematoplatsentarnyy bar'er krys// Byulleten' eksperimental'noy biologii i meditsiny. 2014;15 (3): 366-369.</mixed-citation><mixed-citation xml:lang="en">Tsyganova NA, Khayrullin RM, Terentyuk GS, et al. Pronitsaemost' pegilirovannykh zolotykh nanochastits cherez gematoplatsentarnyy bar'er krys// Byulleten' eksperimental'noy biologii i meditsiny. 2014;15 (3): 366-369.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sharafutdinova LA, Khismatullina ZR, Daminov MR, Valiullin VV. The study of embryotoxic effect of titanium dioxide nanoparticles on rats. Morfologicheskie Vedomosti -Morphological Newsletter. 2017;25(3):37-42.</mixed-citation><mixed-citation xml:lang="en">Sharafutdinova LA, Khismatullina ZR, Daminov MR, Valiullin VV. The study of embryotoxic effect of titanium dioxide nanoparticles on rats. Morfologicheskie Vedomosti -Morphological Newsletter. 2017;25(3):37-42.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
